• Clovis Oncology Inc., of Boulder, Colo. received notification from an independent data monitoring committee that approximately 65 percent of patients in its LEAP pivotal trial of CP-4126 for metastatic pancreatic cancer have been classified as hENT1-low. Clovis licensed CP-4126 from Clavis Pharma ASA, of Oslo, Norway in 2009.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST